You are here: Home » Companies » News
Business Standard

Lupin gets USFDA nod to market generic injection for kidney disease

The product is a generic version of Sanofi Genzyme's Hectorol injection

Press Trust of India  |  New Delhi 

Lupin

Drug firm Monday said it has received approval from the US health regulator to market its generic in the American market.

The company has received approval from the Food and Drug Administration (USFDA) to market its Doxercalciferol injection, 4 mcg/2 mL (2 mcg/mL) multi-dose vials, said in a statement.

The product is a generic version of Sanofi Genzyme's Hectorol injection, it added.

As per the IQVIA MAT September 2018 data, Doxercalciferol injection, 4 mcg/2 mL (2 mcg/mL) multi-dose vials had annual sales of around USD 133 million in the US, said.

The product is indicated for the treatment of in patients with on dialysis, it added.

Shares of Lupin were trading at Rs 853.60 per scrip on BSE, up 0.49 per cent from their previous close.

First Published: Mon, November 05 2018. 15:25 IST
RECOMMENDED FOR YOU